Aarti Pharmalabs reported a robust start to FY27, with standalone net profit after tax (PAT) rising 49% year-on-year to ₹71 crore in Q1FY27, compared to ₹48 crore in the corresponding period last year. Revenue climbed 42% to ₹535 crore from ₹375 crore, while EBITDA grew 40% to ₹133 crore against ₹95 crore previously. The strong financial performance was underpinned by record quarterly sales in the xanthine derivatives vertical and improved utilization across existing manufacturing blocks.

Financial Performance

The company’s profitability expanded alongside top-line growth, reflecting effective cost management and favorable pricing dynamics in key segments. The gross margin reached approximately 56% during the quarter, aided by elevated realization rates in the xanthine business. However, management noted that these margins are subject to normalization as raw material costs stabilize and spot market prices adjust from peak levels observed during recent geopolitical tensions.

Segment Breakdown

Xanthine derivatives emerged as the primary growth engine, contributing 57% of total turnover. This segment recorded its highest-ever quarterly sales, with volume growth estimated at 25% year-on-year. The revenue split within this vertical was heavily skewed towards exports, which accounted for 79% of sales, while domestic sales constituted 21%. The API and intermediates business contributed 30% of turnover, though management highlighted ongoing pricing pressures in existing molecules. To counter this, the company initiated process intensification projects aimed at cost reduction. The CDMO/CMO segment contributed 7% of revenue, with 37 projects currently in commercial stages out of 57 active projects.

Capacity Expansion and Capex

Aarti Pharmalabs completed several strategic expansion projects in Q1FY27. The debottlenecking of the steroid block at Unit 4 in Tarapur enhanced steroidal capacity by 33%. Additionally, new capacity for xanthine derivatives has been commercialized, with trial production ongoing. The company expects to reach over 80% capacity utilization in this segment by FY28.

Looking ahead, both phases of the Atali Block 1 facility, featuring 440 kL reactor capacity, will become fully operational in Q2FY27. This site is primarily engaged in manufacturing CDMO/CMO intermediate steps. Furthermore, the board approved a capex of ₹149 crore for Block 2 at Atali, with groundbreaking expected in Q3FY27. This dedicated block aims to support specific high-volume CDMO projects, aligning with the company’s long-term goal of achieving ₹1,000 crore in CDMO/CMO revenue.

Guidance and Outlook

Management guided for full-year standalone EBITDA margins between 22% and 25% for FY27. While Q1 margins were elevated due to temporary price spikes in raw materials passed through to customers, the company anticipates stabilization in subsequent quarters. For the xanthine segment, annual revenue is projected to land in the range of ₹900 crore to ₹1,100 crore, mitigating potential price declines through increased volume production. The CDMO segment is expected to remain heavy in the second half of the fiscal year, with management targeting 40-50% growth for the segment overall.

What the Numbers Show

The divergence between the 42% revenue growth and 49% net profit growth indicates significant operating leverage in Q1FY27. With EBITDA growing at 40%, the expansion in net profit suggests that fixed costs were effectively spread over a larger revenue base, or that other income/tax efficiencies contributed to the bottom line. Notably, the xanthine segment’s dominance (57% of revenue) contrasts with its lower gross margin profile compared to the high-margin CDMO business (7% of revenue). As the company scales its CDMO operations via the Atali facility, the shift in revenue mix towards higher-margin complex manufacturing could structurally improve blended margins in future quarters, provided volume ramp-ups proceed as planned.

Aarti Pharmalabs Limited reported a 65.4% year-on-year surge in consolidated net profit to ₹761 crore for the first quarter of FY27 (Q1FY27), driven by robust demand in its Xanthine derivatives and Contract Development and Manufacturing Organization (CDMO) segments. Consolidated operational revenue climbed 38.7% to ₹5,358 crore, while EBITDA margins expanded by 10 basis points quarter-on-quarter to 24.75%, reflecting improved operational efficiency despite elevated raw material prices. The strong profitability turnaround was further supported by a gain from foreign exchange movements and a higher share of profit from its joint venture, Ganesh Polychem Limited.

The filing, submitted under Regulation 30 of the SEBI (LODR) Regulations 2015 on August 10, 2026, details the company’s financial performance alongside strategic capacity expansions. Aarti Pharmalabs highlighted that geopolitical tensions have kept raw material prices at elevated levels, though early indications of supply chain easing are emerging. Notably, production at the Unit 4 Steroid API Block was temporarily impacted by a six-week debottlenecking shutdown, which successfully unlocked a one-third capacity increase. The company also disclosed that fair value movements on long-dated USD forward contracts under FVTPL impacted reported profitability, with previous quarterly figures restated accordingly.

Financial Performance Highlights

The company’s consolidated results show significant improvement across key metrics compared to the same period last year. Standalone net profit rose 49.2% year-on-year to ₹713 crore. The following table outlines the key financial figures for Q1FY27:

Standalone operational revenue grew 42.4% to ₹5,346 crore, with standalone EBITDA rising 39.5% to ₹1,327 crore. The net debt-to-equity ratio stood at 0.32x as of FY26, indicating a conservative leverage position amidst aggressive capex plans.

Segmental Growth and Strategic Outlook

Xanthine derivatives remained the largest revenue contributor, accounting for 57% of total revenue in Q1FY27, followed by APIs and intermediates at 30%. The CDMO segment, while contributing 7% of revenue, showed strong momentum with sales reaching ₹276 crore in FY26, up from ₹32 crore in FY22. Management projects CDMO sales to grow by 40-50% in FY27, targeting approximately ₹380 crore.

Geographically, international sales constituted 60% of total revenue, with the Xanthine segment seeing 79% of its sales internationally. This diversification supports the company’s “China+1” strategy, positioning it as a non-Chinese dependent manufacturer with the world’s third-largest Xanthine derivatives capacity.

What the Numbers Show

A critical observation from the filing is the divergence between revenue growth and margin expansion. While operational revenue increased by nearly 39%, EBITDA margins expanded modestly, suggesting that input cost pressures are being partially offset by pricing power and mix shift towards higher-margin CDMO products. Furthermore, the inclusion of Ganesh Polychem Limited as a joint venture from April 1, 2025, has altered the comparability of consolidated figures, with the equity method of accounting now applying. This structural change contributed ₹74 crore to the pre-tax profit in Q1FY27, up from a loss of ₹18 crore in the same period last year, highlighting the growing significance of this partnership in the company’s bottom line.

Looking ahead, Aarti Pharmalabs announced an estimated investment of ₹149 crore for Atali Block 2, a brownfield capex project dedicated to CDMO/CMO activities. Commercialization is targeted for the second half of FY28. The company also initiated R&D investments in TIDES (Peptides & Oligonucleotides) to expand its portfolio capabilities, aiming for a 15-18% revenue and EBITDA CAGR over the next three to four years.